> Skip repeated content

HSS Research Institute

CORRONA Data Collection Program

IRB Number: 23017
(inactive trial)

Institutional Review Board, Hospital for Special Surgery

June 30, 2006

The safety of study participants is our top priority. The trial is approved and periodically reviewed by an Institutional Review Board (IRB), which includes doctors, administrators, ethicists, and members of the general public. The safety of clinical trials is reviewed by the U.S. Food and Drug Administration.

Before enrolling in a clinical trial, the investigator will explain the purpose of the trial, its expected benefits, any possible risks or side effects, and what your role will be. This is the time to ask questions! If you want to join the trial, you must sign the informed consent documents. You can leave a clinical trial at any time without penalty.

For further information, see Understanding Clinical Trials.

Principal Investigator

Allan Gibofsky, MD


Stephen Paget, MD
Joseph A. Markenson, MD
Rachel Glaser, MD
Deborah Miller, Research Assistant
Claudia Reuben, Research Assistant
Daniel Horn, Research Assistant
Janine Fernandez, Office Manager


The Consortium of Rheumatology Researchers of North America, Inc. (CORRONA) Data Collection Program is designed to systematically collect and document use, patterns, effectiveness, and safety of medications such as: Disease Modifying Anti-Rheumatic Drugs (DMARD’s), Nonsteroidal Anti-Inflammatory Drugs (NSAID), biologics, and any other treatments currently used in the management of Rheumatoid Arthritis (RA), Osteoarthritis (OA), Psoriatic Arthritis (PsA), Osteoporosis (OP), and Osteoporosis Risk (OP Risk).  It is anticipated that the study data may help improve the quality of information upon which clinical decisions are based.
CORRONA launched the Data Collection Program in an effort to create an information-gathering network for patients with rheumatic diseases in North America.  This is not a treatment study; it is an observational study.
Approximately 100,000 patients from as many as 90 sites across the United States are expected to participate.

Patients currently enrolled: 263
Enrollment period: Ongoing, no determined end at this time
Duration of follow-up: Never ending; RA patients receive a follow-up questionnaire no more than once every three months, and PsA patients no more than once very 6 months. 

Inclusion/Exclusion Criteria


  • Must have documented diagnosis of Rheumatoid Arthritis, Juvenile Rheumatoid  Arthritis, Osteoarthritis, Psoriatic Arthritis, Osteoporosis, or Osteoporosis Risk.
  • Must be at least 18 years of age
  • Must see a physician at the Hospital for Special Surgery


  • Patients excluded from the study include those excluded based on diagnosis (or age) alone.

Contact Information

Janine Fernandez

Deborah Miller